Source: Google NewsPublished on 2022-08-02
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study USA - English - USA - English - PR Newswire August 2, 2022 NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study USA - English - USA - English PR Newswire
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Patients not patents February 13, 2022 # # # # Patent protection provides an inventor/discoverer with an exclusive right to prevent or stop others from commercially exploiting the patented invention for a set period of time. Patents are supposed to encourage innovation by providing the patent holder with an unchallenged opportunity to develop and profit from an idea. But it could be argued that patents are…
- EJS-ACT PD June 26, 2021 # # # # This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.…
- EverythingALS and NeuroSense take aim at Lou Gehrig's disease - Mugglehead August 2, 2022 EverythingALS and NeuroSense take aim at Lou Gehrig's disease Mugglehead
- A rising tide with liraglutide April 18, 2022 # # # # A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of Parkinson’s. Recently, the results of…
- NeuroSense Therapeutics : Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC - Form 6-K - Marketscreener.com June 1, 2022 NeuroSense Therapeutics : Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC - Form 6-K Marketscreener.com
- NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC USA - English - USA - English - PR Newswire June 1, 2022 NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC USA - English - USA - English PR Newswire
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC - BioSpace June 1, 2022 NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC BioSpace
- Phil Hesketh Event Raises Over $20,000 for Parkinson’s March 21, 2019 On the 28th of February over 140 people gathered at Manly Golf Club to hear Phil Hesketh talk on the Psychology of Pre – Suasion. Over three and a half hours Phil kept the crowd engaged and entertained on topics such as how to handle objections, the real meaning of ‘WIN-WIN’ and ‘Emotional Negotiation’.Shake It Up Board Member Graeme Fear and…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly research review – March 2021 March 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2021. The post is divided into ten parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
- Are we Enterin a new age? February 8, 2022 # # # # A Parkinson’s-focused biotech company called Enterin has had a very busy start to the new year, with publication of some interesting preclinical research and the announcement of Phase II clinical trial results. The clinical trial results met both the primary and secondary endpoints (the pre-determined measures of whether the treatment is effective) indicating a successful…
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- Milestones in Parkinson’s Disease Research and Discovery April 11, 2017 “The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.” Marcel Proust “The process of scientific discovery is, in effect, a continual flight from wonder.” Albert Einstein Preface: Happy birthday to James Parkinson (neurologist, geologist, scientist, activist), born April 11, 1755 and died December 21, 1824. World Parkinson’s Day April 11, 2017. Introduction to…
- NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML USA - English - USA - English - PR Newswire July 28, 2022 NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML USA - English - USA - English PR Newswire